NCEL vs NEUP

NewcelX Ltd. vs Neuphoria Therapeutics Inc. — Valuation Comparison 2026

NCEL

Biotechnology
NewcelX Ltd.
Quality
1.7
out of 10
Value Trap
12
SAFE
Price
$3.54
Last close
Models
7/13
Active
VS

NEUP

Biotechnology
Neuphoria Therapeutics Inc.
Quality
5.4
out of 10
Value Trap
6
SAFE
Price
$5.36
Last close
Models
10/13
Active

Model-by-Model Comparison

ModelType NCEL Fair ValueNCEL Upside NEUP Fair ValueNEUP Upside
Bayesian DCF Intrinsic $0.94 -73.5% $3.75 -30.0%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $6.40 +80.8% $0.61 -88.6%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $2.43 -29.5% $6.04 +12.6%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
RCMH-DCF Intrinsic $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for NCEL vs NEUP — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NCEL vs NEUP — Which Stock Is More Undervalued?

NEUP scores higher with a 5.4/10 quality rating vs NCEL's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing NewcelX Ltd. (NCEL) and Neuphoria Therapeutics Inc. (NEUP) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NCEL currently trades at $3.54 with a QOC of 1.7/10, while NEUP trades at $5.36 with a QOC of 5.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).